.jpg)
METHOD FOR DETERMINING THE EVOLUTION OF ACUTE BRAIN DAMAGE AND PHARMACEUTICAL COMPOSITION FOR TREATING SAME
PCT/ES2021/070856; 202031194
Disclosed is a method for determining the long-term evolution of acute brain damage in individuals, which comprises determining the expression product of at least two of the biomarkers SAA1, S100 beta and TLR4 in a biological sample taken from an individual, and establishing the statistical significance of the concentration of the expression product of the biomarker. Also disclosed is the use of a device for determining the expression product of the biomarkers, and a pharmaceutical composition for use in the treatment of acute brain damage.
A method for determining the evolution of long-term acute brain damage in individuals who have suffered acute brain injuries, both damage caused by intracranial processes and damage that occurs in the central nervous system derived from extracranial processes. Additionally, the method can be used for determining the efficacy of treatment with pharmaceutical compositions on the long-term course of acute brain damage.